Navarra, Spain – August 28, 2025 — Palobiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Dual Antagonist Compounds Targeting A2A and H3 Receptors for the Treatment of Parkinson’s Disease” (Project Code:...